Compare Eli Lilly And Co (LLY) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Mondaycom Ltd — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Mondaycom Ltd trades at $88.96 (market cap $3.76B). The key difference: Eli Lilly And Co is far larger — about 276.6× Mondaycom Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Mondaycom Ltd for 16 Days on average.
| LLY | MNDY | |
|---|---|---|
Market Cap | $1.04T | $3.76B |
Volume | 3,064,878 | 836,200 |
Sector | Health | Technology |
52-Week High | $1.28K | $205.24 |
52-Week Low | $799.57 | $58.81 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $1.09T | $2.92B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Monday.com (MNDY) trades at $88.91, up 6.47% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth to $1.23B in 2025, net income of $118.74M, and consistent earnings beats. Recent news highlights AI integration at Elevate '26 conference and inclusion in growth stock lists. Analyst consensus remains strongly bullish with 17 buy ratings and $108.64 price target.
Outlook remains positive given strong enterprise client growth and AI adoption, though elevated valuation ratios (P/E 37.69) and competitive pressures from Meta's enterprise push present risks. The stock offers growth potential but requires monitoring of profit margin sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
